Abstract
Elevated serum levels of cystatin C are found to be related to poor outcome and metastatic potential of some malignant disorders. To evaluate the clinical prominence of serum cystatin C in diffuse large B-cell lymphoma (DLBCL), blood samples were obtained from 58 patients at the time of diagnosis and paired blood samples were obtained from 22 patients at the time of remission. Also, serum cystatin C level was measured in matched healthy controls. Serum cystatin C levels were significantly more elevated in DLBCL patients than in controls (p < 0.0001). Furthermore, paired-sample analysis revealed that pretreatment cystatin C levels were reduced significantly in patients who achieved remission after therapy (p = 0.016). High serum cystatin C levels were correlated with age over 60 years (p = 0.049), extra-nodal involvement (p = 0.005) and with high serum lactate dehydrogenase (LDH) (p < 0.013). Elevated serum cystatin C levels were associated with extra-nodal involvement and they were significantly reduced to normal range after the remission. However, Kaplan–Meier curves revealed no survival difference in the pretreatment serum cystatin C levels. Therefore, serum cystatin C may be a novel biomarker that reflects tumor burden in DLBCL but bears no prognostic significance regarding survival.
Highlights
The furthermost prevalent subtype of non-Hodgkin lymphoma (NHL) is diffuse large B-cell lymphomas (DLBCL) found in 30%–40% of all cases of lymphoma globally [1,2]
Serum lactate dehydrogenase (LDH) is an example of the most commonly used biomarker in the diagnosis of lymphoma and is correlated to prognosis [4], though it has limited specificity and clinical applications since an increased LDH serum level is noticed in other non-neoplastic diseases, as in myocardial damage [5]
We examined the circulatory cystatin C levels of DLBCL patients
Summary
The furthermost prevalent subtype of non-Hodgkin lymphoma (NHL) is diffuse large B-cell lymphomas (DLBCL) found in 30%–40% of all cases of lymphoma globally [1,2]. Serum lactate dehydrogenase (LDH) is an example of the most commonly used biomarker in the diagnosis of lymphoma and is correlated to prognosis [4], though it has limited specificity and clinical applications since an increased LDH serum level is noticed in other non-neoplastic diseases, as in myocardial damage [5]. 2017, 85, 9 soluble tumor necrosis factor receptor 2 (sTNF-R2) [8]; soluble interleukin-2 receptor (sIL-2R) [9]; nm23-H1 protein [10]; and soluble CD44 [11] These markers are non-specific for the detection of lymphoma as they are increased in other cancer types and even in non-neoplastic conditions [12,13,14]. C in sera of DLBCL patients and prospectively evaluated its potential influence on disease outcome
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
